{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:24:59Z","timestamp":1795040699296,"version":"4.10.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-02-03"],"award-info":[{"award-number":["23-BR-02-03"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-03-05"],"award-info":[{"award-number":["23-BR-03-05"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-05-02"],"award-info":[{"award-number":["23-BR-05-02"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-03-01"],"award-info":[{"award-number":["23-BR-03-01"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-03-07"],"award-info":[{"award-number":["23-BR-03-07"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-02-12"],"award-info":[{"award-number":["23-BR-02-12"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disease characterized by A\u03b2 deposition, tauopathy, neuroinflammation, and impaired cognition. The recent identification of associations between protein kinases and AD pathology has spurred interest in tyrosine kinase inhibitors (TKIs) as potential strategic therapeutic agents for AD. In the present study, we investigated whether the TKIs ibrutinib, PD180970, and cabozantinib, which have different on-targets, selectively regulate AD pathology in 3.5- to 4-month-old 5xFAD mice (a model of the early phase of AD). Ibrutinib (10 mg\/kg, i.p.)\u00a0effectively reduced amyloid-\u03b2 (A\u03b2) plaque number, tau hyperphosphorylation and neuroinflammation in 5xFAD mice. Surprisingly, PD180970 (10 mg\/kg, i.p.)\u00a0did not alter A\u03b2 plaque number or neuroinflammatory responses and exacerbated tau hyperphosphorylation in 5xFAD mice. Cabozantinib (10 mg\/kg, i.p.)\u00a0had no effect on amyloidopathy but partially relieved tau hyperphosphorylation and astrogliosis. Taken together, our results suggest that not all TKIs have therapeutic effects on AD pathology\u00a0in a mouse model of AD. Consequently, optimization of drug dosage, injection periods and administration routes should be considered when repurposing TKIs as novel AD therapeutics.<\/jats:p>","DOI":"10.1186\/s13041-023-01051-9","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T20:04:23Z","timestamp":1692043463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD"],"prefix":"10.1186","volume":"16","author":[{"given":"Hyun-ju","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Woo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Joo","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-8594","authenticated-orcid":false,"given":"Hyang-Sook","family":"Hoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"21","key":"1051_CR1","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.3390\/ijms232112924","volume":"23","author":"U Sehar","year":"2022","unstructured":"Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid beta in aging and Alzheimer\u2019s disease. Int J Mol Sci. 2022;23(21):12924.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1051_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3390\/ph15121546","volume":"15","author":"A Lui","year":"2022","unstructured":"Lui A, Vanleuven J, Perekopskiy D, Liu D, Xu D, Alzayat O, Elgokhy T, Do T, Gann M, Martin R, et al. FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders. Pharmaceuticals (Basel). 2022;15(12):1546.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1051_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fncel.2013.00189","volume":"7","author":"V Tell","year":"2013","unstructured":"Tell V, Hilgeroth A. Recent developments of protein kinase inhibitors as potential AD therapeutics. Front Cell Neurosci. 2013;7:189.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"1051_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13332","volume":"20","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Jeon SG, Kim J, Kang RJ, Kim SM, Han KM, Park H, Kim KT, Sung YM, Nam HY, et al. Ibrutinib modulates Abeta\/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer\u2019s disease. Aging Cell. 2021;20(3): e13332.","journal-title":"Aging Cell"},{"issue":"1","key":"1051_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12974-022-02549-0","volume":"19","author":"J Kim","year":"2022","unstructured":"Kim J, Lee HJ, Park JH, Cha BY, Hoe HS. Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38\/STAT3 signaling. J Neuroinflammation. 2022;19(1):187.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1051_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12974-019-1561-x","volume":"16","author":"KY Ryu","year":"2019","unstructured":"Ryu KY, Lee HJ, Woo H, Kang RJ, Han KM, Park H, Lee SM, Lee JY, Jeong YJ, Nam HW, et al. Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT\/STAT3 signaling. J Neuroinflammation. 2019;16(1):190.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1051_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13041-020-00673-7","volume":"13","author":"SG Jeon","year":"2020","unstructured":"Jeon SG, Lee HJ, Park H, Han KM, Hoe HS. The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice. Mol Brain. 2020;13(1):131.","journal-title":"Mol Brain"},{"key":"1051_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903309","volume":"13","author":"J Kim","year":"2022","unstructured":"Kim J, Kim SJ, Jeong HR, Park JH, Moon M, Hoe HS. Inhibiting EGFR\/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A. Front Immunol. 2022;13: 903309.","journal-title":"Front Immunol"},{"issue":"2","key":"1051_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3233\/JAD-2009-1062","volume":"17","author":"Z Jing","year":"2009","unstructured":"Jing Z, Caltagarone J, Bowser R. Altered subcellular distribution of c-Abl in Alzheimer\u2019s disease. J Alzheimers Dis. 2009;17(2):409\u201322.","journal-title":"J Alzheimers Dis"},{"key":"1051_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijdevneu.2015.03.003","volume":"43","author":"A Muche","year":"2015","unstructured":"Muche A, Bigl M, Arendt T, Schliebs R. Expression of vascular endothelial growth factor (VEGF) mRNA, VEGF receptor 2 (Flk-1) mRNA, and of VEGF co-receptor neuropilin (Nrp)-1 mRNA in brain tissue of aging Tg2576 mice by in situ hybridization. Int J Dev Neurosci. 2015;43:25\u201334.","journal-title":"Int J Dev Neurosci"},{"issue":"12","key":"1051_CR11","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","volume":"7","author":"L Hirsch","year":"2021","unstructured":"Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol. 2021;7(12):1815\u201323.","journal-title":"JAMA Oncol"},{"key":"1051_CR12","first-page":"6769017","volume":"2019","author":"A Uche","year":"2019","unstructured":"Uche A, Sila C, Tanoura T, Yeh J, Bhowmick N, Posadas E, Figlin R, Gong J. Brain complete response to cabozantinib prior to radiation therapy in metastatic renal cell carcinoma. Case Rep Urol. 2019;2019:6769017.","journal-title":"Case Rep Urol"},{"issue":"7","key":"1051_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737140.2017.1344553","volume":"17","author":"A Abdelaziz","year":"2017","unstructured":"Abdelaziz A, Vaishampayan U. Cabozantinib for the treatment of kidney cancer. Expert Rev Anticancer Ther. 2017;17(7):577\u201384.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1051_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ebiom.2019.10.036","volume":"50","author":"S Sn","year":"2019","unstructured":"Sn S, Pandurangi J, Murumalla R, Dj V, Garimella L, Acharya A, Rai S, Paul A, Yarreiphang H, Pillai MS, et al. Small molecule modulator of aggrephagy regulates neuroinflammation to curb pathogenesis of neurodegeneration. EBioMedicine. 2019;50:260\u201373.","journal-title":"EBioMedicine"},{"issue":"10","key":"1051_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.trecan.2016.09.001","volume":"2","author":"K Pozo","year":"2016","unstructured":"Pozo K, Bibb JA. The emerging role of Cdk5 in cancer. Trends Cancer. 2016;2(10):606\u201318.","journal-title":"Trends Cancer"},{"issue":"10","key":"1051_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.420","volume":"5","author":"S Senese","year":"2014","unstructured":"Senese S, Lo YC, Huang D, Zangle TA, Gholkar AA, Robert L, Homet B, Ribas A, Summers MK, Teitell MA, et al. Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development. Cell Death Dis. 2014;5(10): e1462.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1051_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jnc.13411","volume":"136","author":"MR Minter","year":"2016","unstructured":"Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer\u2019s disease. J Neurochem. 2016;136(3):457\u201374.","journal-title":"J Neurochem"},{"issue":"1","key":"1051_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12974-020-01820-6","volume":"17","author":"R Ismail","year":"2020","unstructured":"Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, Kjeldsen PL, Stokholm MG, Gottrup H, Eskildsen SF, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer\u2019s disease: a longitudinal PET study. J Neuroinflammation. 2020;17(1):151.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1051_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/msj.20163","volume":"77","author":"MJ Metcalfe","year":"2010","unstructured":"Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer\u2019s disease. Mt Sinai J Med. 2010;77(1):50\u20138.","journal-title":"Mt Sinai J Med"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01051-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-023-01051-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01051-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T14:20:10Z","timestamp":1700230810000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-023-01051-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1186\/s13041-023-01051-9","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"18 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo experiments were approved by the institutional biosafety committee (IBC) and were performed in accordance with approved animal protocols and guidelines established by the institutional animal care and use committee of Korea Brain Research Institute (KBRI, approval numbers: IACUC-19\u201300049 and IACUC-22\u201300044).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The patents regarding the efficacy of ibrutinib on AD pathology were licensed to PharmacoRex on March 3, 2023.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}